Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

Completed · Not applicable

Conditions studied: Multiple Sclerosis

In brief

Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the expression of SOCS3 in DCs.

Key facts

Study ID

NCT00630721

Run by

University of North Carolina, Chapel Hill

People needed

56

Starts

2007-09-01

Expected to finish

2011-03-15

Last updated by the study team

2018-10-18

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Confirmed diagnosis of MS
• Age 18-60 years, inclusive
• Expanded disability status of 0-6.5
• Give written informed consent prior to any testing under this protocol

Where it is running

• University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.